Renovaro Inc. (NASDAQ:RENB) Major Shareholder Anderson Wittekind William Sells 20,000 Shares

Renovaro Inc. (NASDAQ:RENB) major shareholder Anderson Wittekind William sold 20,000 shares of the company’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $1.58, for a total transaction of $31,600.00. Following the completion of the transaction, the insider now owns 1,243,499 shares of the company’s stock, valued at approximately $1,964,728.42. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Anderson Wittekind William also recently made the following trade(s):

• On Thursday, June 27th, Anderson Wittekind William sold 14,671 shares of Renovaro stock. The stock was sold at an average price of $1.50, for a total transaction of $22,006.50.
• On Friday, June 14th, Anderson Wittekind William sold 50,000 shares of Renovaro stock. The stock was sold at an average price of $1.58, for a total transaction of $79,000.00.

Renovaro Stock Down 4.5 %

NASDAQ RENB traded down $0.07 on Thursday, hitting $1.50. The stock had a trading volume of 773,678 shares, compared to its average volume of 496,393. The company’s 50-day moving average is $1.46 and its two-hundred day moving average is $2.63. The stock has a market cap of $221.27 million, a price-to-earnings ratio of -2.07 and a beta of 0.44. Renovaro Inc. has a one year low of $0.39 and a one year high of $5.25.

Renovaro (NASDAQ:RENB) last posted its quarterly earnings data on Wednesday, May 15th. The company reported ($0.08) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in RENB. SG Americas Securities LLC acquired a new stake in Renovaro during the first quarter valued at approximately $46,000. Vanguard Group Inc. lifted its stake in Renovaro by 904.0% during the first quarter. Vanguard Group Inc. now owns 3,916,672 shares of the company’s stock valued at $10,379,000 after purchasing an additional 3,526,565 shares during the last quarter. Finally, Tidal Investments LLC acquired a new stake in Renovaro during the first quarter valued at approximately $98,000. 71.41% of the stock is currently owned by institutional investors.

Renovaro Company Profile

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.